Phaseline

Targets › IGA

IGA (B-cell antigen receptor complex-associated protein alpha chain): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Respiratory; next expected readout Jul 2028.

Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. (UniProt, P11912)

Open in Phaseline: the race on IGA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
BiotestTrimodulin (BT588)
Polyclonal immunoglobulin preparation (IgG, IgM, IgA)
IGG, IGM, IGAPhase 3Community-acquired PneumoniaJul 2028

Conditions

Community-acquired Pneumonia (1)

Modalities

small molecule (1)

Companies

Biotest (1)

Related targets

IGG (1) IGM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.